Clinical Research Directory

Inclusion Criteria: * Ability to understand the nature of the study and voluntarily sign the Informed Consent Form (ICF). * Adult participants ≥18 years and ≤65 years of age at the time of signing the ICF. * Meet the diagnostic criteria for Allergic Rhinitis (AR), diagnosed with Perennial Allergic Rhinitis (PAR), with a PAR history of at least 1 year, and regularly exposed to perennial allergens in daily life accompanied by related nasal symptoms. * Positive serum allergen-specific Immunoglobulin E(IgE) test results at screening, confirming that the participant is sensitized to at least one perennial allergen in their current environment, accompanied by consistent clinical symptoms. * Medical history prior to the screening visit shows that the participant received Intranasal Corticosteroids(INCS) and/or other AR medications within the past 1 year but had inadequate symptom control. * From the screening visit to randomization, the participant must meet the following symptom score requirements at screening and baseline: rTNSS ≥ 6 and Nasal Congestion score ≥ 2. * During the screening/run-in period, compliance with diary card recording and adherence to background medication during the run-in period must both be ≥ 80%. * For participants with comorbid asthma, the investigator or a relevant specialist must confirm that the asthma is stable. Exclusion Criteria: * Not enough washing-out period for previous therapy. * Concurrent disease/status which may potentially affect the efficacy/safety judgement. * Organ dysfunction. * Pregnancy. * Other.